Comentario al artículo “Dosis de enoxaparina asociada a disminución de riesgo de muerte en COVID-19” / Comment on article “Enoxaparin dose associated with decreased risk of death in COVID-19”
##plugins.themes.themeEleven.article.main##
Keywords
Tromboembolia Venosa, Anticoagulantes, SARS-CoV-2, Heparinas / Venous Thromboembolism, Anticoagulants, Heparins
Resumen
En la presente carta al editor, a propósito del artículo “Dosis de enoxaparina asociada a disminución de riesgo de muerte en COVID-19”, se discute el papel de las estrategias de tromboprofilaxis y el potencial rol de las heparinas en relación con la COVID-19.
In this letter to the editor, apropos of the article “Enoxaparin dose associated with decreased risk of death in COVID-19”, it is discussed the role of the current thromboprophylactic strategies, as well as the potential role of heparins in the management of COVID-19.
Referencias
Joanico-Morales B, Gaspar-Chamu AD, Salgado-Jiménez MLÁ, Rodríguez-Echeverría G. Dosis de enoxaparina asociada a disminución de riesgo de muerte en COVID-19. Rev Med Inst Mex Seguro Soc. 2022;60(1):33-39.
Lawler PR, Goligher EC, Berger JS, Neal MD, McVerry BJ, et al. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. N Engl J Med. 2021;385(9):790-802. doi: 10.1056/ NEJMoa2105911.
Goligher EC, Bradbury CA, McVerry BJ, Lawler PR, Berger JS, Gong MN, et al. Therapeutic Anti-coagulation with Heparin in Critically Ill Patients with Covid-19. N Engl J Med. 2021;385(9):777-89. doi: 10.1056/NEJMoa2103417.
INSPIRATION Investigators. Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial. JAMA. 2021;325(16):1620-30. doi: 10.1001/ jama.2021.4152.
Demelo-Rodriguez P, Farfán-Sedano AI, Pedrajas JM, Llamas P, Sigüenza P, Jaras MJ, et al. Bleeding risk in hospitalized patients with COVID-19 receiving intermediate- or therapeutic doses of thromboprophylaxis. J Thromb Haemost. 2021;19(8):1981-9. doi: 10.1111/jth.15400.
Porres-Aguilar M, Pérez-Nieto OR, Anaya-Ayala JE, Zamarrón-López EI, Hernández-Gilsoul T, Aurón M. Prophylactic anticoagulation in hospitalized patients with COVID-19: less is better. Gac Med Mex. 2021; 157(6):640. doi: 10.24875/GMM.M21000631.